Approved ICI for treatment of unresectable stage III or metastatic NSCLC include several anti-PD-1 and anti-PD-L1 agents, and more recently, the combination of anti-PD-1 with anti-CTLA-4 has been added to this arsenal [6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.